TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER (TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER).

How it works

Travasol 2.75% with electrolytes in dextrose 20% provides amino acids for protein synthesis, dextrose as a caloric source, and electrolytes for maintenance of fluid and electrolyte balance. Dextrose stimulates insulin release, promoting cellular uptake of glucose and amino acids, while electrolytes help maintain osmolality and acid-base balance.

What the body does with it

Metabolism	Amino acids are metabolized via transamination, deamination, and urea cycle; dextrose undergoes glycolysis and oxidative phosphorylation; electrolytes are excreted or reabsorbed by kidneys.
Excretion	Renal: 100% as free water, electrolytes, and dextrose metabolites; no biliary or fecal elimination.
Half-life	Not applicable; TRAVASOL is a mixture of dextrose, electrolytes, and amino acids with no defined terminal elimination half-life as individual components are metabolized or excreted rapidly.
Protein binding	Negligible (<5%); no specific binding proteins.
Volume of Distribution	Distributes into total body water (approximately 0.6 L/kg); dextrose and electrolytes rapidly equilibrate with extracellular fluid.
Bioavailability	Intravenous: 100%.
Onset of Action	Intravenous: Immediate upon infusion; clinical effects (hydration, electrolyte replenishment, caloric supply) begin within minutes.
Duration of Action	Duration is dependent on infusion rate and metabolic demands; typically 2-4 hours after infusion for electrolyte and fluid effects, with dextrose metabolism continuing for 1-2 hours post-infusion.

Classification & Brands

Dosing & administration

Intravenous infusion: Typical adult dose is 1-2 L/day of TRAVASOL 2.75% with 20% dextrose, administered as continuous infusion via central line. Rate should be adjusted based on metabolic and fluid needs.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in severe renal impairment (CrCl < 30 mL/min) without appropriate monitoring. For CrCl 30-50 mL/min: reduce infusion rate by 50% and monitor electrolytes closely. For CrCl > 50 mL/min: no adjustment needed.
Liver impairment	Contraindicated in Child-Pugh class C cirrhosis. For Child-Pugh class B: reduce nitrogen load by 50% and monitor ammonia levels. For Child-Pugh class A: standard dosing can be used with caution.
Pediatric use	Weight-based dosing: 0.1-0.3 g amino acids/kg/day (increasing gradually to 1.5-3 g/kg/day) with dextrose 20% adjusted to maintain glucose homeostasis. Typical volume: 100-150 mL/kg/day for neonates, 80-100 mL/kg/day for children.
Geriatric use	Elderly patients: start at lower end of dosing range (1 L/day) due to reduced renal function and increased risk of fluid overload. Monitor serum electrolytes and glucose closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Breastfeeding	Dextrose and electrolytes pass into breast milk in small amounts. Amino acids are normally present in breast milk. M/P ratio not established. Considered compatible with breastfeeding when used as indicated. Monitor infant for signs of electrolyte imbalance or glucose intolerance.
Teratogenic Risk	Travasol 2.75% with electrolytes in dextrose 20% is a parenteral nutrition solution. Dextrose at high concentrations may cause fetal hyperglycemia and hyperinsulinemia, especially in third trimester. Amino acids and electrolytes are generally considered safe in recommended doses. However, there is insufficient data to rule out teratogenic risk. Use during pregnancy only if clearly needed.

Warnings & precautions

■ FDA Black Box Warning

Risk of profound hypoglycemia or hyperglycemia; hyperosmolar nonketotic coma; electrolyte imbalances; volume overload; pulmonary edema; and metabolic acidosis. Contains aluminum that may be toxic with prolonged administration in patients with renal impairment or premature infants.

Side Effect Profile

Serious Effects

Absolute Contraindications

Absolute: Hypersensitivity to any component, severe metabolic acidosis, hyperglycemic coma, anuria, oliguric renal failure, and uncontrolled heart failure. Relative: Severe hepatic insufficiency, hyperosmolality, electrolyte disorders, and pulmonary edema.

Clinical Precautions

Precautions

Monitor serum glucose, electrolytes, and fluid status closely. Avoid in patients with severe hyperglycemia, uremia, or hepatic failure. Use cautiously in renal impairment, heart failure, or hypervolemia. Risk of central line-associated bloodstream infections with IV administration.

Clinical Tips & Counseling

Drug interactions

Loading safety data…